Oryzon, Roche ink potential $500M deal on epigenetic modulator
Oryzon Genomics SA is getting $21 million in up-front and near-term milestones and could earn more than $500 million in total from a partnering deal with Roche AG on its lysine-specific demethylase-1 (LSD1) inhibitor program.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter